A phase I study of Summary Previously we described the clinical aspects of a phase I study of prolonged continuous infusion of low-dose recombinant interleukin-2 (rIL-2). In the present paper we report several immunological effects in 13 patients with melanoma and renal cell cancer treated on an out-patient basis with rIL-2 for uninterrupted periods ranging from 5 to 18 weeks. Groups of three patients were treated at following dose levels 0.18, 0.6, 1.8 or 6 x 106 IU m-2 24 h-' and one patient was treated with 3 x 106 IU m2 24 h-'. Prolonged rIL-2 treatment resulted in a dose-dependent and sustained increase in the percentage and absolute number of (CD56+, CD8dim) natural killer cells. Within this population a preferential increase in the CD56bnght cells with low expression of CD16 was observed. The CD27 antigen was also upregulated in the CD56bnigltCD16 dim population. This increase of NK cells was accompanied by an enhancement of the cytotoxic capacity of the peripheral lymphocytes. No consistent signs of T cell activation or expansion were noted.
The lymphokine interleukin-2 (IL-2) was originally described as a growth factor for T lymphocytes (Morgan et al., 1976) . Preclinical studies demonstrated that IL-2 also exerts promoting effects on natural killer (NK) cells (Henny et al., 1981) , lymphokine activated killer (LAK) cells (Lotze et al., 1981; Grimm et al., 1982) , B-lymphocytes (Waldmann et al., 1984) and monocytes (Malkovsky et al., 1987) . The cloning of the IL-2 gene (Taniguchi et al., 1983) led to production of Escherichia coli derived non-glycosylated recombinant IL-2 (rIL-2) with biological activity comparable with the glycosylated natural IL-2 molecule (Rosenberg et al., 1984; Liang et al., 1985) . Preclinical and clinical studies have demonstrated the potential of rIL-2 as an immuno-modulating and anti-tumour agent. Administration of high-dose rIL-2, either as bolus injection or as continuous intravenous infusion, may result in objective anti-tumour responses in up to 25% of patients with advanced cancer, especially renal cell cancer and melanoma (Negrier et al., 1989; Rosenberg et al., 1989) . Treatment with rIL-2 may lead to substantial shifts in lymphocyte subpopulations, the in vivo generation of cells with LAK activity, augmentation of NK activity, enhanced antibody dependent cellular cytotoxicity (ADCC), and the release of a variety of other cytokines (Hank et al., 1988; Gemlo et al., 1988; Schaafsma et al., 1991) . These effects are related to the dosage and duration of the rIL-2 treatment (Creekmore et al., 1989; Gambacorti-Passerini et Hank et al., 1988; Kohler et al., 1989; Lotze et al., 1985; Sondel et al., 1988; Thompson et al., 1988) .
The substantial and cumulative toxicity means that high dose rIL-2 is usually administered for periods less than a week. There has been recent interest in prolonged administration of lower, less toxic doses rIL-2. Data are emerging on the clinical and immunological effects of prolonged and continued rIL-2 treatment (Caligiuri et al., 1991; Soiffer et al., 1992) . From 1989 to 1991, we conducted a phase I study of prolonged continuous intravenous infusion of rIL-2 (EuroCetus) at doses ranging from 0.18 to 9 x 106 IU m-2 24 h-' in 22 patients with renal cell cancer and melanoma administered on an out-patient basis. As reported in a previous paper (Vlasveld et al., 1992) 
Materials and methods

Patients and treatment
In this phase I study, low dose rIL-2 was continuously infused through a central venous access on an out-patient basis. After reconstitution rIL-2 (EuroCetus, Amsterdam, the Netherlands) was diluted in 10 ml sterile water containing 2% human serum albumin and infused through a long infusion device by a portable pump.
As shown in Table I four groups of three patients, treated at the dose levels 0.18 x 106 IU (group I), 0.6 x 106 IU (group II), 1.8 x 106 IU (group III) and 6 x 106 IU m-2 24 h-I (group IV), were evaluated for immunological effects.
An additional patient (pt 13) was treated with 3 x 106 IU ml-2 24 h-'. In this patient the dose was escalated from 3 to 6 x 106 IU m2 24 h-' after 7 weeks. In another patient (pt 10) of group IV, the dose was escalated from 6 to 9 x 106 IU m-2 24 h-' after 10 weeks of treatment. (Tsudo et al., 1989) ), anti-HLA-DR (DK22, Dako), anti-CD38 (ATI, NKI), anti-CD1 la (NKI-L7, NKI), anti-CD1 la (activation epitope) (NKI-L16, NKI), anti-CD18 (CLB-LFA1/1, CLB), anti-CD58 (TS2/9, kindly provided by Dr (FCS) and 100 U ml-' penicillin and 100 pg ml-' kanamycin. Proliferation assays were carried out in Iscove's modified Dulbecco's medium supplemented with 5% inactivated, pooled human serum, 100 U ml-' penicillin and 100 jig ml-' kanamycin.
Cytotoxicity
To limit the effects of inter-assay variation, the PBL taken before, during and after treatment from one patient were tested in a single cytotoxicity experiment. This experimental set-up made it necessary to cryopreserve patients' PBL. Previous experiments with PBL from healthy donors had shown that incubation overnight at 37°C is needed to restore the cytotoxic capacity of cryopreserved cells (unpublished data). Patients' PBL were incubated overnight in medium alone or in medium with 600 IU rIL-2 ml1' (EuroCetus) at 37°C in a humidified atmosphere with 5% CO.
NK activity was defined by the ability of the PBL to lyse K562 target cells, LAK activity was defined by the ability to lyse Jiyoye (Burkitt lymphoma) target cells, and ADCC (antibody dependent cellular cytotoxicity) activity was defined by the ability of PBL to lyse Jiyoye target cells in the presence of R24.3, a rat IgG2b mAb directed against a non-polymorphic epitope on HLA class II. The cytotoxic capacities of PBL in the three assays was also determined after additional in vitro stimulation with 600 IU rIL-2 ml-' for 18 h and were defined as NKa, LAKa, ADCCa, respectively.
The target cells K562 and Jiyoye were labelled with 5'Cr by incubation with Na5' Chromate (specific activity 13-22 GBq mg-' chromium, Amersham, Buckinghamshire, UK), 6.4 MBq 10-6 cells, for 60-120min at 37°C. After washing, R24.3 mAb (100 igml-') was added to part of the Jiyoye cells.
Target cells were dispensed in 96 well round bottom microtiter plates (Sterilin, Hounslow, UK) at a concentration of 103 cells/well and mixed with effector cells at six effector/ target (E/T) ratios between 80:1 and 2.5:1 in triplicate in a final volume of 2001jI. Plates were centrifuged for 2 min at 1,000 r.p.m. and incubated for 4 h at 37°C in humidified air with 5% CO2. After incubation, plates were centrifuged (2 min, 1,000 r.p.m.), 100 jil supernatant was harvested from each well and the 5'Cr content determined in a Packard Tricarb Liquid Scintillation Counter (Downers Grove, Ill, USA). The percentage specific 5'Cr release was calculated with the formula:
T-S % specific 5'Cr release=
where T = c.p.m. in test sample, M = maximal releasable label in 2% Triton-X100, 0.5% SDS, 1% sodium deoxycholate, 10 nM EDTA and S = spontaneously released label from target cells in medium. The cytotoxic capacity of the patients' PBL was expressed in Lytic Units (30%) 10-6 effector cells, calculated by the method described (Pross et al., 1981) , where one Lytic Unit is defined as the number of effector cells that produce 30% lysis of 1,000 target cells.
Proliferation assays
After thawing PBL were cultured in medium alone, or in medium with 6 IU rIL-2 ml-' (21 pM) or 600 IU rIL-2 ml' (2.1 nM). At a concentration of 6 IU ml1 rIL-2 + 70% of the high affinity (CD25/p75) IL-2 receptor is occupied, with only minimal or no binding to intermediate affinity (p75) In the six patients treated at the two lowest dose levels (0.18 and 0.6 x 106 IU m-2 24 h-') for a maximum of 9 weeks, we observed no significant effect on the total lymphocyte count, the lymphocyte subpopulations, or on the spontaneous cytotoxic capacity and proliferative response of the isolated PBL (Tables II-IV) . In pt I of group I and pt 6 of group II, a small increase in NK and ADCC was noted only after in vitro stimulation with rIL-2. No LAKa activity was observed.
1.8 x 10J IU m-2 24 h'-I (group III) Three patients were treated at this dose level for 6, 9 and 17 weeks. In two patients (pts 7 and 9) the absolute number of CD56+ NK cells more than doubled (Table II) , without changes in the T cell subpopulation. During treatment, the changes in the cytotoxic capacity of the PBL were variable, but after in vitro rIL-2 stimulation a pronounced increase in killing capacity was seen in these patients (Table III) I  pt I  pre  740  81  61  21  11  15  32  16  max  1660  79  61  24  10  14  26  6  pt 2  pre  2380  75  45  44  27  29  32  5  max  2460  77  46  40  27  31  41  9  pt 3  pre  800  60  37  26  32  29  38  max  750  42  27  28  49  49  32  Group II  pt 4  pre  930  55  36   -19  17  10  15  max  1060  58  39  26  18  15  8  17  pt 5  pre  2410  75  51  22  21  11  38  20  max  1600  71  57  17  29  20  23  22  pt6  pre  1120  73  44  46  14  17  24  6  max  1240  70  48  53  26  26  24  16  Group III  pt 7  pre  2570  80  44  38  33  10  26  13  max  3100  59  29  36  53  34  17  30  pt 8  pre  4820  77  69  13  18  9  27  13  max  2780  72  62  17  19  12  22  16  pt 9  pre  790  71  53  17  13  20  13  1   max  1470  64  45  25  32  33  26  3  Group IV  pt 10 pre  1340  62  36  37  27  19  20  13  max  6320  15  10  51  76  58  57  77  pt 11 pre  2340  63  47  25  19  18  20  15  max  7380  16  13  51  90  90  53  65  pt 12 pre  950  58  42  26  20  19  10  max  1380  13  10  65  70  50  10  76  pt 13 pre  1800  80  56  30  16  17  50  12  max  1240  55  46  36  36  35  54  31  Max: maximal effect on immunological parameter during rIL-2 treatment. In all but one patient (pt 9) this effect was maximal at the end of treatment. 6x J0'IUm-224h-' (group IV) Three patients were treated at this dose level for 7, 14 and 18 weeks respectively. Pt 13 was initially treated with 3 x 10' IU ml-2 24 h-' and after 7 weeks the dose was escalated to 6 x 106 IU m-2 24 h-I for another 7 weeks. During the first weeks of treatment no consistent changes in the lymphocyte count were observed but after prolonged treatment a sustained increase of the lymphocyte count was noted. In patient 10 the dose was escalated to 9 x 106 IU m2 24 h-1 after 10 weeks of treatment without evident effect on the lymphocyte count. In pt 13 no changes in the total lymphocyte count were observed, not even after dose escalation.
No changes in the monocyte count occurred in any of the patients. Since the most striking immunological effects were noted in these patients, these results will be discussed in detail.
A: Immunophenotyping of lymphocyte subpopulations (group IV) In all three patients treated at the dose level of 6 x 106 IU m 2 24 h-' there was a pronounced shift within the lymphocyte population. The percentage of CD3+ (T) cells decreased to about one quarter of the baseline levels, while the absolute number of CD3+ cells remained the same throughout the treatment (Table II) . The percentage and absolute number of CD56+ cells showed a dramatic and sustained increase during treatment. Figure 1 shows a representative graph of the changes in numbers of CD3+ and CD56+ lymphocytes. After treatment the number of CD3+ and CD56+ cells returned to pre-treatment values. Within the CD56+ cell compartment, a preferential increase in the percentage of cells with high expression of CD56 (CD56b'rh') was noted (Figure 2 ). In addition there was a preferential increase in the percentage of cells with low expression of CD16 (CD16dim) and of CD8 (CD8dim) cells (Figure 2 (Figure 3b ).
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No changes occurred within the T cell population. Before and during treatment 15-40% of the CD3+ population were CD8bright, 15-45% expressed CD25. Nearly all T cells expressed CD27 and CD2, while p75 was virtually negative. LFA-1 was present on virtually all CD3+ cells, while <30% of the CD3+ lymphocytes expressed CD54 (tested on a limited number of samples in pts 10 and 11).
6.
-IL B: Cytotoxic capacity (group IV)
Cytotoxicity of PBL without in vitro rIL-2 stimulation In 36 patients 10, 11 and 12 the PBL showed a considerable increase in NK and ADCC activity during treatment (Table  III) . The time-course of this increase in cytotoxic capacity is shown in Figure 4 . Cytotoxicity only became apparent in the samples taken after 6 weeks of treatment and then remained elevated throughout the entire treatment period.
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To exclude the possibility that the increased cytotoxic capacity was solely the result of an increased number of NK cells, we also expressed the results in Lytic Units 10-6 104 CD56+ cells. After this re-calculation the cytotoxic capacity of the PBL sampled during treatment remained enhanced. These results suggest that enhanced activation of NK cells is induced by the rIL-2 treatment. The limited number of PBL precluded cytotoxicity assays after T cell depletion. In patient 13, ADCC was only observed after dose escalation. The cytotoxic capacity of the PBL from three patients (pts 10, 11 and 12) treated at the highest dose level. The PBL were cultured overnight in medium without rIL-2 and the capacity of the PBL to lyse K562 was determined in a standard 5'Cr release assay (NK activity). Solid bars represent the cytotoxic capacity of the isolated peripheral blood lymphocytes (PBL), hatched bars represent the cytotoxic capacity of the isolated PBL after correction for the number of CD56+ natural killer cells (CD56).
Cytotoxic capacity of the PBL after in vitro stimulation with rIL-2 In the two patients (10 and 11) tested, NKa, LAKa and ADCCa were enhanced during treatment, while in patient 13 these cytotoxic activities increased only after dose escalation (Table III) .
C: In vitro proliferation assay (Group IV)
The PBL of two (pts 10 and 11) of the three tested patients showed an increased response to 600 IU rIL-2 ml-', while one of them (pt 11) even responded to 6 IU rIL-2 ml-' (Table IV) , suggesting the presence of lymphocytes expressing the high-affinity IL-2 receptor.
No enhanced proliferation was noted upon in vitro stimulation with CD3 and/or CD28 antibodies in any of the patients. The reduced response to anti-CD3 in patients 10 and 11 may be related to a diminished percentage of T cells during treatment. Serum anti IL-2 antibodies and soluble IL-2 receptor (groups I-IV) Before and after treatment no IgG and IgM antibodies against IL-2 were detected.
The plasma level of the soluble IL-2 receptor (sIL-2R) was determined on cryopreserved plasma isolated before, at regular intervals during and after rIL-2 treatment. Before and after treatment the plasma sIL-2R concentration was below 200 U ml-'. There was a close relationship (r = 0.948) between the dose and the plasma sIL-2R concentration as measured after 3 and 6 weeks of rIL-2 treatment. During further prolonged rIL-2 treatment the plasma sIL-2R tended to decrease. After dose escalation, no increase in the plasma sIL-2 was noted. There was no correlation between the plasma sIL-2R concentration and the absolute number of CD25+ cells (r = 0.204) or any other immunological parameter.
Discussion
In this study we investigated the immuno-modulating effects of prolonged continuous infusion of EuroCetus rIL-2 and demonstrated that this mode of administration for a period of more than 6 weeks may result in a sustained activation of the immunesystem. We confirm the data from others that prolonged treatment with rIL-2 results primarily in an increased number and activity of NK cells in a dose-dependent way (Caligiuri et al., 1991; Soiffer et al., 1992) .
The most striking and consistent immunological effects occurred at a dose 6 x 106 IU m-2 24 h-'. In these patients we noted a sustained and marked increase of NK cells with enhanced cytotoxic capacity of the PBL, without alterations within the T cell subpopulations.
Particularly in the two patients treated for 14 and 18 weeks, a steady time-dependent lymphocytosis occurred with a 10-20 fold increase in the number of natural killer cells.
Natural killer cells, phenotypically best defined as CD3-CD56+ lymphocytes, comprise 10-15% of normal resting blood lymphocytes (Nagler et al., 1989; Lanier et al., 1986; Robertson et al., 1990b (CD56dimCD16brghl), and a small subset of NK cells express CD56 at a high level (CD56bright) with low or no expression of CD16 (Nagler et al., 1989; Lanier et al., 1986) . This and other studies indicate that rIL-2 treatment leads to a preferential increase in the relative and absolute number of the CD56brightCD16dim and CD56bright-CD16-subsets (Ellis et al., 1988; Soiffer et al., 1992; Weil-Hillman et al., 1989; Urba et al., 1990) .
The shift within the NK subsets has several consequences for the phenotypic and functional characteristics of the NK cells. The intermediate affinity IL-2 receptor p75 is expressed by the majority of resting NK cells (Caligiuri et al., 1990; Nagler et al., 1989; Ohashi et al., 1989; Tsudo et al., 1986; Voss et al., 1990) and only a small subpopulation of NK (the CD56bNight) cells express the high-affinity IL-2 receptor (CD25/ p75) (Caligiuri et al., 1990; Nagler et al., 1990) . We and others (Thompson et al., 1989; Voss et al., 1990; WeilHillman et al., 1990) have demonstrated that the CD25 expression on CD56+ cells remains virtually negative during prolonged in vivo rIL-2 treatment, suggesting down regulation of the high-affinity IL-2 receptor on the CD56bnrit NK subset . Nevertheless, in patient 11 the appearance of a small subset of NK cells expressing the high affinity IL-2 receptor is suggested by the fact that the PBL of this patient displayed an enhanced proliferative response upon in vitro stimulation with 6 IU ml-' rIL-2 (Weil-Hillman et al., 1989; .
During rIL-2 treatment we and others observed an increase of CD56+ cells expressing the adhesion molecule CD54 (ICAM-1) (Triozzi et al., 1992) , indicating activation as has been demonstrated after in vitro stimulation (Robertson et al., 1990a) . We noted that the increase occurred primarily on the CD56bnigh'CD 16dim cells.
Unexpectedly, we found that prolonged rIL-2 treatment resulted in an increased expression of CD27 on CD56+ cells, particularly on the CD56bngh'CD16dim population. CD27, initially thought to be a T cell-specific antigen present on the majority of T cells, plays a prominent role in T cell activation (Lier van et al., 1987; Sugita et al., 1991) . Very recently it has been demonstrated that CD27 is also expressed at a low level on resting NK cells, especially on the CD56bNigh, population and that the expression is upregulated after in vitro stimulation with rIL-2 (Sugita et al., 1992) . Our data confirm that CD27 is present on a small percentage of resting NK cells and show that CD27 is upregulated on a subpopulation after in vivo rIL-2 treatment.
These phenotypic changes, reflecting the presence of an 565 activated NK cell population induced by rIL-2 treatment, were accompanied by an increased natural killer (NK) activity and antibody dependent cellular cytotoxicity (ADCC), which was further enhanced after additional in vitro stimulation with rIL-2. Lymphokine activated killer (LAK) activity measured after in vitro rIL-2 stimulation was also increased during treatment. Increased cytotoxic capacity of PBL during rIL-2 treatment has been described by others using freshly isolated cells (Creekmore et al., 1989; Kohler et al., 1989; Thompson et al., 1989; Urba et al., 1990 ). Because we used cryopreserved lymphocytes in order to test all samples in a single experiment, no quantitative comparison with our data can be made.
Since T cell activation, determined by an increase of CD3+ cells expressing CD25 or HLA-DR, has only been observed after short-term treatment with high-dose rIL-2 (Thompson et al., 1989; Yoshino et al., 1991) , it is not surprising that we did not find indications for T cell expansion or activation after prolonged infusion of relatively low dose rIL-2. The CD4/CD8b Mht ratio remained unchanged during treatment and there was no increased expression of markers associated with T cell activation, such as CD27 or CD25. One patient (pt 9), however, treated at 1.8 x 106 IU m 2 24 h'-had subtle signs of T cell activation after 3 weeks of treatment. A low expression of the high-affinity IL-2 (CD25/p75) was present on CD3+ cells, the isolated PBL showed increased proliferation upon T cell specific stimulation, and the patient had disproportionally elevated serum soluble IL-2 receptor levels, which may be indicative for lymphocyte activation (Voss et al., 1989; Rubin et al., 1990) .
The observed pattern of the serum soluble IL-2 receptor levels in our patients is in agreement with that observed by others (Bogner et al., 1992; Lissoni et al., 1991 : Lotze et al., 1987 Voss et al., 1989) showing that during prolonged intermittent or continuous rIL-2 treatment, the serum levels gradually increase during the first week(s) followed by a plateau level or a gradual decline as rIL-2 treatment continues. Although in vitro studies indicate that soluble IL-2 receptor may be released upon stimulation of T and B lymphocytes (Hofmann et al., 1992) , the source of sIL-2R in patients treated with rIL-2 for advanced cancer is obscure. In this study we confirm that the serum sIL-2R levels are closely related to the dose of rIL-2 (Bogner et al., 1992) . As also reported by others (Lotze et al., 1987) , the serum sIL-2R level could be correlated with the clinical toxicity observed in our patients (Vlasveld et al., 1992) , which reached a peak after 3 weeks of treatment followed by a decrease despite continuation of the rIL-2 treatment.
In the clinical analysis of the present study (Vlasveld et al., 1992 ) a short term partial remission was observed in one patient (pt 8). The immunological effects in this patient were not different from those observed in non responding patients.
In conclusion, prolonged continuous intravenous administration of rIL-2 results in a dose-dependent increase in the number of NK cells, preferentially of the CD56brightCD16dim fraction. The NK cells had phenotypical signs of activation and displayed enhanced functional activity. During treatment we observed no expansion or activation of T cells. In contrast to the observed transient pattern of clinical toxicity and eosinophilia (Vlasveld et al., 1992) , the changes within the NK population were sustained.
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